MGMarcia Rubia Rodrigues Gonçalves

Marcia Rubia Rodrigues Gonçalves

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marcia Rubia Rodrigues Gonçalves has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metapneumovirus-associated necrotizing disseminated acute leukoencephalopathy

    by Sara Caixeta de Souza, Ahmed Haydar, João Lucas Silva Santana, Artur Martins De March, Guilherme Diogo Silva, Fernando Freua, Luis Filipe de Souza Godoy, Leandro Tavares Lucato, Adalberto Studart Neto, Rodrigo Holanda Mendonça, et al.

  • Open Access

    Guidelines for Parkinson's disease management part II: consensus from the movement disorders scientific department of the Brazilian Academy of Neurology – non-motor symptoms

    by Débora Palma Maia, Rubens Gisbert Cury, Pedro Renato P. Brandão, Francisco E. C. Cardoso, Ana Paula Bertholo, André Carvalho Felicio, Arlete Hilbig, Bruno Lopes Santos Lobato, Eline Rozária F. Barbosa, Elizabeth Maria A. B. Quagliato, et al.

    The treatment of Parkinson's disease (PD) is a challenge, especially because it is considered highly individualized. The Brazilian Academy of Neurology (ABN) has identified the need to disseminate knowledge about its management, adapting the best evidence to the Brazilian population. The present article aims to report the recommendations for the treatment of non-motor symptoms of PD, developed by a group of specialists in movement disorders from the ABN's scientific department. In 2021, the first part, referring to the motor symptoms of PD, was published. The main non-motor symptoms were addressed—among them neuropsychiatric symptoms, such as depression, anxiety, cognitive alteration, and psychosis—as well as the possible recommended therapies and medications used to control pain, sleep disorders, and dysautonomia.


  • Real-world application of 2022 diagnosis criteria and proposed classification of optic neuritis

    by Sara Terrim, Guilherme Diogo Silva, Fernando Cavalcanti de Sá e Benevides Falcao, Clarissa dos Reis Pereira, Thais de Souza Andrade Benassi, Ida Fortini, Marcia Rubia Rodrigues Gonçalves, Luiz Henrique Martins Castro, Samira Luisa Apostolos Pereira, Luiz Roberto Comerlatti, et al.

  • Clinical, cerebrospinal fluid, and neuroimaging findings in COVID-19 encephalopathy: a case series

    by Raphael L. Tuma, Bruno F. Guedes, Rafael Carra, Bruno Iepsen, Júlia Rodrigues, Antonio Edvan Camelo-Filho, Gabriel Kubota, Maíra Ferrari, Adalberto Studart-Neto, Mariana Hiromi Oku, et al.

    Objective To describe the clinical, neurological, neuroimaging, and cerebrospinal fluid (CSF) findings associated with encephalopathy in patients admitted to a COVID-19 tertiary reference center. Methods We retrospectively reviewed records of consecutive patients with COVID-19 evaluated by a consulting neurology team from March 30, 2020 through May 15, 2020. Results Fifty-five patients with confirmed SARS-CoV-2 were included, 43 of whom showed encephalopathy, and were further divided into mild, moderate, and severe encephalopathy groups. Nineteen patients (44%) had undergone mechanical ventilation and received intravenous sedatives. Eleven (26%) patients were on dialysis. Laboratory markers of COVID-19 severity were very common in encephalopathy patients, but did not correlate with the severity of encephalopathy. Thirty-nine patients underwent neuroimaging studies, which showed mostly non-specific changes. One patient showed lesions possibly related to CNS demyelination. Four had suffered an acute stroke. SARS-CoV-2 was detected by RT-PCR in only one of 21 CSF samples. Two CSF samples showed elevated white blood cell count and all were negative for oligoclonal bands. In our case series, the severity of encephalopathy correlated with higher probability of death during hospitalization (OR = 5.5 for each increment in the degree of encephalopathy, from absent (0) to mild (1), moderate (2), or severe (3), p < 0.001). Conclusion In our consecutive series with 43 encephalopathy cases, neuroimaging and CSF analysis did not support the role of direct viral CNS invasion or CNS inflammation as the cause of encephalopathy.


  • Open Access

    Air and Water Quality Improvement during COVID-19 Lockdown

    by Pedro Silva, Mariana Ávila, Márcia Gonçalves


  • Open Access

    Clinical, cerebrospinal fluid and neuroimaging findings in COVID-19 encephalopathy: a case series

    by Raphael Tuma, Bruno Guedes, Rafael Carra, Bruno Iepsen, Júlia Rodrigues, Antonio Edvan Camelo-Filho, Gabriel Kubota, Maíra Ferrari, Adalberto Studart Neto, Mariana Hiromi Manoel Oku, et al.

    Objective: To describe the clinical, neurological, neuroimaging and cerebrospinal fluid (CSF) findings associated with encephalopathy in patients admitted to a COVID-19 tertiary reference center. Methods: We retrospectively reviewed records of consecutive patients with COVID-19 evaluated by a consulting neurology team from March 30, 2020 through May 15, 2020. Results: Fifty-five patients with confirmed SARS-CoV-2 were included, 43 of whom showed encephalopathy, and were further divided into mild, moderate and severe encephalopathy groups. Nineteen patients (44%) had undergone mechanical ventilation and received intravenous sedatives. Eleven (26%) patients were on dialysis. Laboratory markers of COVID-19 severity were very common in encephalopathy patients, but did not correlate with the severity of encephalopathy. Thirty-nine patients underwent neuroimaging studies, which showed mostly non-specific changes. One patient showed lesions possibly related to CNS demyelination. Four had suffered an acute stroke. SARS-CoV-2 was detected by RT-PCR in only one of 21 CSF samples. Two CSF samples showed elevated white blood cell count and all were negative for oligoclonal bands. In our case series the severity of encephalopathy correlated with higher probability of death during hospitalization (OR = 5.5 for each increment in the degree of encephalopathy, from absent (0) to mild (1), moderate (2) or severe (3), p<0.001). Conclusion: In our consecutive series with 43 encephalopathy cases, neuroimaging and CSF analysis did not support the role of direct viral CNS invasion or CNS inflammation as the cause of encephalopathy.


  • Open Access

    Neurological consultations and diagnoses in a large, dedicated COVID-19 university hospital

    by Adalberto Studart-Neto, Bruno Fukelmann Guedes, Raphael de Luca e Tuma, Antonio Edvan Camelo Filho, Gabriel Taricani Kubota, Bruno Diógenes Iepsen, Gabriela Pantaleão Moreira, Júlia Chartouni Rodrigues, Maíra Medeiros Honorato Ferrari, Rafael Bernhart Carra, et al.

    Background: More than one-third of COVID-19 patients present neurological symptoms ranging from anosmia to stroke and encephalopathy. Furthermore, pre-existing neurological conditions may require special treatment and may be associated with worse outcomes. Notwithstanding, the role of neurologists in COVID-19 is probably underrecognized. Objective: The aim of this study was to report the reasons for requesting neurological consultations by internists and intensivists in a COVID-19-dedicated hospital. Methods: This retrospective study was carried out at Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil, a 900-bed COVID-19 dedicated center (including 300 intensive care unit beds). COVID-19 diagnosis was confirmed by SARS-CoV-2-RT-PCR in nasal swabs. All inpatient neurology consultations between March 23rd and May 23rd, 2020 were analyzed. Neurologists performed the neurological exam, assessed all available data to diagnose the neurological condition, and requested additional tests deemed necessary. Difficult diagnoses were established in consensus meetings. After diagnosis, neurologists were involved in the treatment. Results: Neurological consultations were requested for 89 out of 1,208 (7.4%) inpatient COVID admissions during that period. Main neurological diagnoses included: encephalopathy (44.4%), stroke (16.7%), previous neurological diseases (9.0%), seizures (9.0%), neuromuscular disorders (5.6%), other acute brain lesions (3.4%), and other mild nonspecific symptoms (11.2%). Conclusions: Most neurological consultations in a COVID-19-dedicated hospital were requested for severe conditions that could have an impact on the outcome. First-line doctors should be able to recognize neurological symptoms; neurologists are important members of the medical team in COVID-19 hospital care.


  • Open Access

    MR Imaging Features of Adult-Onset Neuronal Intranuclear Inclusion Disease May Be Indistinguishable from Fragile X–Associated Tremor/Ataxia Syndrome

    by I.G. Padilha, R.H. Nunes, F.A. Scortegagna, J.L. Pedroso, V.H. Marussi, M.R. Rodrigues Gonçalves, O.G.P. Barsottini, A.J. da Rocha

    We have read with great interest the article by Sugiyama et al[1][1] published in the November 2017 edition of the American Journal of Neuroradiology , which described typical brain MR imaging findings in adult-onset neuronal intranuclear inclusion disease (NIID). The authors highlighted the